The DEA recently increased its quota for psilocybin for 2022, as well as for the legal production of psychedelic drugs such as MDMA and DMT, in response to heightened demand and interest within the scientific community to research the effectiveness of these psychedelic drugs in the treatment of mental health disorders.
The Petition To Reschedule Psilocybin
Now, a petition filed earlier this week by a Seattle doctor Sunil Aggarwal, who specializes in end-of-life care, is urging the agency to reschedule psilocybin as a less-restricted Schedule II drug, Marijuana Moment reported.
The document highlighted psilocybin's relatively low potential for abuse and "exceptional promise in relieving debilitating symptoms in those with intractable and otherwise untreatable illness," such as severe anxiety and depression.
"The original placement of psilocybin," the petition says, "was the result of a substantial overestimation of the risk of harm and abuse potential, not rigorous science."
Once/if the main psychoactive component of psychedelic mushrooms is rescheduled, federal barriers to psilocybin research would also be removed.
The document cites recent comments by Nora Volkow, director of the National Institute on Drug Abuse (NIDA), which shed light the on bureaucratic challenges scientists face in terms of marijuana research in the U.S.
A Schedule I designation under the Controlled Substances Act "detracts researchers who want to investigate it because it's just much more cumbersome than doing studies with other substances," Volkow who is also a researcher, said earlier.
Cancer Patients Bid To Use Psilocybin Dismissed
In the meantime, Aggarwal's federal petition filed by his lawyers came on the heels of a rejection of a lawsuit by the doctor and cancer patients seeking access to psilocybin to help treat end-of-life depression and anxiety. On Monday, a three-judge panel of the US Court of Appeals for the Ninth Circuit dismissed the lawsuit on procedural grounds.
In a letter sent earlier, the DEA said that there was no way for Aggarwal's clinic, the Advanced Integrative Medical Sciences (AIMS) Institute, to dispense a synthetic form of the psilocybin under state and federal right-to-try (RTT) laws, leaving patients with no path forward, the lawyers argued.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.